--- title: "Biomea Fusion | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285997457.md" datetime: "2026-05-11T21:05:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285997457.md) - [en](https://longbridge.com/en/news/285997457.md) - [zh-HK](https://longbridge.com/zh-HK/news/285997457.md) --- # Biomea Fusion | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.17. EBIT: As of FY2026 Q1, the actual value is USD -13.2 M. Biomea Fusion, Inc. operates as one reportable segment and has not generated any revenue from product sales since its inception, expecting continued and increasing operating losses as clinical development advances . #### Operational Metrics (Three Months Ended March 31) - **Net Loss:** Biomea Fusion, Inc. reported a net loss of - $12,415 thousand for 2026, a significant decrease from the - $29,262 thousand net loss in 2025 . - **Total Operating Expenses:** Total operating expenses decreased to $12,774 thousand in 2026 from $29,712 thousand in 2025 . - **Research and Development (R&D) Expenses:** R&D expenses decreased by $13,777 thousand, from $22,897 thousand in 2025 to $9,120 thousand in 2026 . This reduction was primarily due to a $7,600 thousand decrease in external costs, including a $3,800 thousand decrease in clinical activities and a $1,900 thousand decrease in preclinical and exploratory programs, alongside a $4,500 thousand decrease in personnel-related expenses and a $1,700 thousand decrease in facilities and other allocated expenses . Clinical research organization expenses for COVALENT-101, COVALENT-102, COVALENT-111, and COVALENT-112 were $0 in 2026, compared to $1,001 thousand, $614 thousand, $2,242 thousand, and $502 thousand respectively in 2025 . Conversely, COVALENT-211 and COVALENT-212 incurred $743 thousand and $562 thousand respectively in 2026, up from $0 in 2025, and GLP-131 expenses rose to $1,425 thousand in 2026 from $0 in 2025 . - **General and Administrative (G&A) Expenses:** G&A expenses decreased by $3,161 thousand, from $6,815 thousand in 2025 to $3,654 thousand in 2026 . This was mainly driven by a $1,900 thousand decrease in personnel-related expenses and a $1,100 thousand decrease in corporate-related expenses . - **Loss from Operations:** Loss from operations decreased to - $12,774 thousand in 2026 from - $29,712 thousand in 2025 . - **Change in fair value of common warrant liability:** This resulted in a - $581 thousand impact in 2026, compared to $0 in 2025 . - **Gain on sale of property and equipment:** Biomea Fusion, Inc. recognized a gain of $510 thousand in 2026, compared to $0 in 2025, primarily from the sale of laboratory equipment . - **Interest and other income, net:** This decreased slightly from $450 thousand in 2025 to $430 thousand in 2026 . #### Cash Flow (Three Months Ended March 31) - **Net cash used in operating activities:** - $11,669 thousand in 2026, compared to - $25,667 thousand in 2025 . - **Net cash provided by investing activities:** $550 thousand in 2026, compared to $0 in 2025, primarily from the sale of property and equipment . - **Net cash provided by financing activities:** $0 in 2026, compared to $3,252 thousand in 2025 . - **Net decrease in cash, cash equivalents, and restricted cash:** - $11,119 thousand in 2026, compared to - $22,415 thousand in 2025 . - **Cash, cash equivalents, and restricted cash at the end of the period:** $45,062 thousand in 2026, compared to $36,233 thousand in 2025 . #### Unique Metrics - **Accumulated Deficit:** As of March 31, 2026, Biomea Fusion, Inc. had an accumulated deficit of $461.5 million . - **Common Stock Outstanding:** 72,299,440 shares as of March 31, 2026 . - **Warrant Liability:** The fair value of warrant liability was $18,372 thousand as of March 31, 2026 . #### Future Outlook and Strategy Biomea Fusion, Inc. is a clinical-stage company focused on developing novel small molecule therapies for diabetes and obesity . Its lead drug candidate, icovamenib, is currently undergoing two Phase II clinical trials (COVALENT-211 and COVALENT-212) for type 2 diabetes, with topline results from the COVALENT-112 trial in type 1 diabetes reported in April 2026 . The company also anticipates Phase I trial data for BMF-650, a GLP-1 RA for obesity, in the second quarter of 2026 . Biomea Fusion, Inc. plans to seek partnerships for its oncology assets (BMF-500) to focus internal resources on metabolic disorders . The company’s existing cash of $45.1 million as of March 31, 2026, is projected to fund operations only into the first quarter of 2027, necessitating additional capital for future operations . ### Related Stocks - [BMEA.US](https://longbridge.com/en/quote/BMEA.US.md) ## Related News & Research - [Biomea Fusion doses first patient in OPAL trial of icovamenib plus semaglutide for obesity](https://longbridge.com/en/news/295786405.md) - [Biomea Fusion Q2 loss narrows, cash runway into Q2 2027](https://longbridge.com/en/news/295013243.md) - [Paramount Skydance rilis transkrip paparan kinerja kuartal II 2026](https://longbridge.com/en/news/295579688.md) - [Here's How Much $1000 Invested In Agnico Eagle Mines 5 Years Ago Would Be Worth Today](https://longbridge.com/en/news/295580635.md) - [How Investors Are Reacting To Boston Scientific (BSX) Recall Wave After Strong Mid‑Year Results](https://longbridge.com/en/news/295426841.md)